These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 27297780)

  • 1. Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
    van Wamel A; Sontum PC; Healey A; Kvåle S; Bush N; Bamber J; de Lange Davies C
    J Control Release; 2016 Aug; 236():15-21. PubMed ID: 27297780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin Nanoparticle of Paclitaxel (Abraxane) Decreases while Taxol Increases Breast Cancer Stem Cells in Treatment of Triple Negative Breast Cancer.
    Yuan H; Guo H; Luan X; He M; Li F; Burnett J; Truchan N; Sun D
    Mol Pharm; 2020 Jul; 17(7):2275-2286. PubMed ID: 32485107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma.
    Kotopoulis S; Stigen E; Popa M; Safont MM; Healey A; Kvåle S; Sontum P; Gjertsen BT; Gilja OH; McCormack E
    J Control Release; 2017 Jan; 245():70-80. PubMed ID: 27871988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
    Bhattacharyya J; Bellucci JJ; Weitzhandler I; McDaniel JR; Spasojevic I; Li X; Lin CC; Chi JT; Chilkoti A
    Nat Commun; 2015 Aug; 6():7939. PubMed ID: 26239362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System.
    Hama M; Ishima Y; Chuang VTG; Ando H; Shimizu T; Ishida T
    ACS Appl Mater Interfaces; 2021 May; 13(17):19736-19744. PubMed ID: 33881292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Study of bioequiavailability of paclitaxel for Injection (Albumin Bound) and abraxane and the efficacy of extension treatments in patients with metastatic breast cancer].
    Bian L; Geng CZ; Ouyang QC; Hu XC; Peng YY; Xiao JY; Wang MX; Yang N; Yuan J; Wang YM; Jiang ZF
    Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1236-1241. PubMed ID: 29747311
    [No Abstract]   [Full Text] [Related]  

  • 8. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases.
    Ernsting MJ; Murakami M; Undzys E; Aman A; Press B; Li SD
    J Control Release; 2012 Sep; 162(3):575-81. PubMed ID: 22967490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.
    Feng Z; Zhao G; Yu L; Gough D; Howell SB
    Cancer Chemother Pharmacol; 2010 Apr; 65(5):923-30. PubMed ID: 19685054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FPPRGD2 and 18F-FDG PET of response to Abraxane therapy.
    Sun X; Yan Y; Liu S; Cao Q; Yang M; Neamati N; Shen B; Niu G; Chen X
    J Nucl Med; 2011 Jan; 52(1):140-6. PubMed ID: 21149494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial.
    Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I
    JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and characterization of paclitaxel palmitate albumin nanoparticles with high loading efficacy: an in vitro and in vivo anti-tumor study in mouse models.
    Chen H; Huang S; Wang H; Chen X; Zhang H; Xu Y; Fan W; Pan Y; Wen Q; Lin Z; Wang X; Gu Y; Ding B; Chen J; Wu X
    Drug Deliv; 2021 Dec; 28(1):1067-1079. PubMed ID: 34109887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-nanoparticle conjugate constructed with trastuzumab and nanoparticle albumin-bound paclitaxel for targeted therapy of human epidermal growth factor receptor 2-positive gastric cancer.
    Xiong J; Han S; Ding S; He J; Zhang H
    Oncol Rep; 2018 Mar; 39(3):1396-1404. PubMed ID: 29328489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of albumin-embedded paclitaxel nanoparticles to tumors.
    Karmali PP; Kotamraju VR; Kastantin M; Black M; Missirlis D; Tirrell M; Ruoslahti E
    Nanomedicine; 2009 Mar; 5(1):73-82. PubMed ID: 18829396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.
    Dranitsaris G; Yu B; Wang L; Sun W; Zhou Y; King J; Kaura S; Zhang A; Yuan P
    J Oncol Pharm Pract; 2016 Apr; 22(2):205-11. PubMed ID: 25316611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence assessment of high-capacity polymeric micelle nanoformulation of paclitaxel and Abraxane® in rodent and non-human primate models using a stable isotope tracer assay.
    Hwang D; Vinod N; Skoczen SL; Ramsey JD; Snapp KS; Montgomery SA; Wang M; Lim C; Frank JE; Sokolsky-Papkov M; Li Z; Yuan H; Stern ST; Kabanov AV
    Biomaterials; 2021 Nov; 278():121140. PubMed ID: 34634661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
    Saif MW
    JOP; 2013 Nov; 14(6):686-8. PubMed ID: 24216565
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
    Grilley-Olson JE; Keedy VL; Sandler A; Moore DT; Socinski MA; Stinchcombe TE
    Oncologist; 2015 Feb; 20(2):105-6. PubMed ID: 25616430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative Proteomic Analysis of Cellular Resistance to the Nanoparticle Abraxane.
    Zhao M; Li H; Bu X; Lei C; Fang Q; Hu Z
    ACS Nano; 2015 Oct; 9(10):10099-112. PubMed ID: 26324059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of Abraxane that combines human IL15 fused with an albumin-binding domain on murine models of pancreatic ductal adenocarcinoma.
    Hsu FT; Tsai CL; Chiang IT; Lan KH; Yueh PF; Liang WY; Lin CS; Chao Y; Lan KL
    J Cell Mol Med; 2022 Apr; 26(7):1955-1968. PubMed ID: 35174623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.